CAR-NK-CD19

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCAR-NK-CD19
Drug Alias NameCAR-NK-CD19
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Gao Boren Hospital Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Gao Boren Hospital Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A